Track market-moving stories before they get noisy

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict damage, pain and even death if not treated.

As New World screwworm continues to threaten the U.S.1 -- recently prompting several states to issue formal orders requiring treatment of domestic animals as part of cross-border animal movement from infested areas -- Zoetis is closely monitoring the situation and is committed to helping veterinarians and dog owners be prepared with solutions. Under an EUA, the FDA authorizes the use of a medication in an emergency to treat or prevent life-threatening diseases or conditions when certain criteria are met.

“At Zoetis, our highest priority is protecting the health and well-being of animals,” said Abhay Nayak, EVP and President, U.S. Commercial Operations at Zoetis. “The Emergency Use Authorization for Simparica Trio provides an important new tool in the fight against New World screwworm, a devastating parasite that can cause severe suffering in dogs. With this milestone, Simparica Trio helps simplify parasite protection for dogs with a single monthly chew—supporting both routine control and New World screwworm response needs.”

“We are deeply committed to supporting our customers with trusted, science-driven solutions—especially when rapid response and preparedness on key public health issues are critical. This Emergency Use Authorization for Simparica Trio builds on Zoetis’ expanding, multi-species set of solutions to help address New World screwworm across both companion animals and livestock,” Nayak continued. “Zoetis remains dedicated to advancing animal health and delivering the confidence our customers rely on, backed by Zoetis’ science, quality and manufacturing scale – so more animals can be protected, more consistently.”

Simparica Trio was the first product FDA-approved to provide all-in-one protection for dogs against heartworm disease, ticks and fleas, roundworms, hookworms, and prevents flea tapeworm infections by killing fleas in a single monthly chewable. It is FDA-approved to kill six species of ticks, including the Gulf Coast tick – providing comprehensive tick protection. While found all over the nation, the Gulf Coast tick is native to Southern U.S. states, including Texas.

Pet owners are encouraged to work closely with their veterinarian if they have any concerns about New World screwworm or other parasites. Reports of any suspicious wounds, maggots, or infestations should be made to a local veterinarian, state animal health official or the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS). USDA APHIS animal health contacts can be found at https://www.aphis.usda.gov/contact/animal-health.

As the leading animal health company, Zoetis has long supported a One Health approach to emerging and transboundary infectious diseases and has a strong track record of quickly developing innovative solutions to provide veterinarians and animal owners with the right mix of tools to prevent, control and treat disease in animals.

IMPORTANT SAFETY INFORMATION for Simparica Trio
Use with caution in dogs with a history of seizures. Simparica Trio contains sarolaner, a member of the isoxazoline class which has been associated with neurologic adverse reactions including tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. The safe use of Simparica Trio has not been evaluated in breeding, pregnant, or lactating dogs. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. See Full Prescribing Information at SimparicaTrioPI.com.

Treatment of New World screwworm in Other Species
In addition to the EUA for Simparica Trio, Zoetis offers Dectomax®-CA1 Injectable (doramectin injection), the only nonprescription conditionally approved parasite control product labeled for prevention and treatment of infestations caused by NWS larvae in cattle and for prevention of reinfestation for 21 days. This conditional approval applies to beef cattle, female dairy cattle less than 20 months of age, pregnant beef cows, newborn calves and bulls. Dectomax-CA1 is not for use in calves to be processed for veal. Dectomax-CA1 is not for use in female dairy cattle 20 months of age or older, except under the conditions of the Emergency Use Authorization (EUA) granted on May 19, 2026.

The U.S. Food and Drug Administration has issued an Emergency Use Authorization (EUA) for the use of the approved/conditionally approved products Dectomax/Dectomax-CA1 for the following indications:

The prevention and treatment of infestations caused by Cochliomyia hominivorax larvae (myiasis) in dairy cattle (lactating dairy cows, dry dairy cows, and replacement dairy heifers 20 months of age and older), except for calves to be processed for veal. The prevention of infestations caused by C. hominivorax larvae (myiasis) in swine, sheep except for lactating sheep, and deer. The prevention of infestations caused by C. hominivorax larvae (myiasis) in horses 1 year old and older. Early detection of New World screwworm and rapid response are crucial to protecting the health of companion animals and livestock.

Emergency Use Authorization for Simparica Trio for New World Screwworm
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Simparica Trio is not approved for this use.

Simparica Trio is approved for other uses in dogs and puppies.

For additional information on the EUA, please refer to the Simparica Trio EUA Fact Sheet.

Limitations of Authorized Use
Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Approved Indications for Simparica Trio
Simparica Trio is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and hookworm (L4, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala) infections. Simparica Trio kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. Simparica Trio is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

Please refer to the following fact sheets for additional information:
EUA - Simparica Trio Fact Sheet
EUA - Dairy Cattle, Swine, Sheep and Deer Fact Sheet
EUA - Horse Fact Sheet
For more information on NWS, visit FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies

Dectomax-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under NADA 141-616.
Important Information:
Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
Dectomax-CA1 Injectable (Cattle only), as authorized under the Conditional Approval for use against New World screwworm, has a 35-day pre-slaughter withdrawal period. Do not use in calves to be processed for veal. Do not use in female dairy cattle 20 months of age or older, except under the conditions of the Emergency Use Authorization. Use in dogs may result in fatalities.
Dectomax/Dectomax-CA1 Injectable Emergency Use Authorization, authorized for the duration of the emergency declaration, does not provide full or conditional approval, but the Center for Veterinary Medicine (CVM) at the Food and Drug Administration (FDA) has determined that Dectomax/Dectomax-CA1 may be effective and safe. Dectomax/Dectomax-CA1 Injectable, as authorized under the Emergency Use Authorization for use against New World screwworm, has a 35-day pre-slaughter withdrawal period for lactating dairy cattle, dry dairy cattle, replacement dairy heifers, sheep and deer, and a 24-day pre-slaughter withdrawal period for swine. Treated calves and calves born to treated cows should not be processed for veal. Withhold milk from dairy cattle for 468 hours (19.5 days) after treatment has ended. Not for use in lactating sheep. Not for use in horses less than 1 year of age.

DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements which reflect the current views of Zoetis with respect to regarding products, product approvals or licenses, products under development and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

ZTS-COR
ZTS-IR
ZTS-CA

1 APHIS. Current Status of New World Screwworm | Screwworm.gov Accessed 6/3/26.

More News From Zoetis Inc.

Which Pet Stock Should Get Your Tail Wagging in 2024?Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.

Chief Executive Officer Kristin Peck said the quarter fell short of the company’s expectations amid declining veterinary clinic visits, more selective spending by pet owners and greater promotional activity from competitors. Zoetis lowered its full-year outlook, now expecting organic operational revenue to decline 3% to 1% and adjusted net income to decline 9% to 5%.

Get Zoetis alerts:

Companion-Animal Demand and Competition Weigh on Results MarketBeat Week in Review – 07/31 - 08/04Peck said veterinary clinic visits continued a multiyear decline, while price increases in pet care have outpaced broader consumer inflation. Pet owners have become more selective in their spending, with clinic revenue shifting toward urgent and emergency care and premium preventative and chronic-care products facing pressure, she said.

Global companion-animal revenue was $1.7 billion, down 6% in the quarter. U.S. companion-animal revenue declined 11% to $1 billion, while international companion-animal revenue increased 5% to $664 million.

Rising Dividend Make Zoetis a Doggone WinnerKey dermatology revenue fell 16% to $395 million globally. In the U.S., dermatology revenue declined 18% to $251 million, as canine pruritic clinic visits fell by more than 2%, according to Peck. Chief Financial Officer Wetteny Joseph said the company’s U.S. dermatology franchise retained about 86% in-clinic share during the quarter, though share declined 5 percentage points sequentially and 10 points from a year earlier.

Zoetis has begun using targeted promotions, rebates and other “growth-to-net” investments to protect volume and share rather than lowering list prices, Peck said. Those actions can include clinic-specific promotions, cross-portfolio bundles and point-of-sale discounts for pet owners.

“We are not changing the list price of our products,” Peck said in response to analyst questions. “What we’re talking about is investments in what, in the industry, they’ll call growth to net.”

The Simparica franchise generated $442 million in revenue, flat globally. Simparica Trio revenue fell 1% to $350 million, while Simparica revenue rose 4% to $91 million. International franchise growth was offset by U.S. pressure from softer flea, tick and heartworm visits, as well as a more competitive and promotional marketplace.

U.S. Simparica franchise revenue declined 6% to $308 million. Joseph said Simparica Trio held approximately 21% in-clinic share in U.S. oral parasiticides, nearly double its nearest competitor, and its puppy share was about 28%.

OA Pain Products Show Mixed Performance Global osteoarthritis pain monoclonal-antibody revenue was $147 million, down 3%. Canine OA pain products Librela and Lenivia produced $105 million in revenue, down 8%, while feline OA pain products Solensia and Portela generated $42 million, up 12%.

U.S. canine OA pain revenue declined 24% to $34 million, reflecting a strong prior-year comparison, softer clinic traffic and affordability pressures on premium therapies. International OA pain revenue increased 7% to $96 million, supported by early launches of long-acting Lenivia and Portela in the European Union and Canada.

Peck said Zoetis expects U.S. approval of long-acting Cytopoint later in 2026. The company also said early experience with Lenivia and Portela has been encouraging and that it expects further market expansion in the coming year.

Diagnostics and Livestock Provide Offsets Companion-animal diagnostics revenue rose 12% to $118 million, driven by adoption of technologies including Vetscan Imagyst and Vetscan OptiCell. During the quarter, Zoetis completed its acquisition of VitalRADS, a veterinary teleradiology services platform, expanding its capabilities in veterinary imaging interpretation.

Peck said commercial validation of Vetscan OmniMax, a multimodal chemistry platform that the company views as a potential blockbuster opportunity, remains expected by year-end.

Livestock revenue increased 11% to $731 million, with U.S. livestock revenue rising 23% to $222 million. Growth was driven by cattle and poultry, improved product supply and elevated U.S. demand for Dectomax and other injectable parasiticides in connection with the New World screwworm outbreak.

Joseph said several factors behind the U.S. livestock performance were transitory, including supply timing and screwworm-related demand. Zoetis expects U.S. livestock growth to moderate to the mid-single-digit range in the second half, while citing mid- to high-single-digit growth as a sustainable range for the business’ broader fundamentals.

Guidance Reduced as July Trends Show No Stabilization Zoetis now expects 2026 revenue of $9.12 billion to $9.32 billion. It projected adjusted net income of $2.57 billion to $2.62 billion, adjusted diluted EPS of $6.15 to $6.25, and reported diluted EPS of $5.55 to $5.65.

Joseph said the revised forecast incorporates sales trends through July, which had “not yet indicated market stabilization.” The upper end assumes competitive and pricing pressures remain contained, while the lower end contemplates accelerated pressure, greater dermatology and parasiticide share losses, continued July-like weakness and slower livestock uptake.

The company also cited an additional foreign-exchange headwind of roughly $60 million to $65 million to revenue and about $30 million to profit compared with its prior outlook.

Zoetis repurchased more than $550 million of shares during the quarter. Joseph said the company is maintaining investment in R&D and selected commercial priorities while pursuing cost and productivity actions; adjusted SG&A declined 4% operationally in the quarter.

Separately, Peck said Abhay Nayak was promoted to executive vice president and president of U.S. Commercial Operations. Jay Saccaro will join Zoetis on Aug. 17 as executive vice president, chief financial officer and chief operating officer, a newly created role overseeing finance as well as global manufacturing and supply. Joseph will remain a special advisor on financial matters until early 2027 to support the transition.

About Zoetis (NYSE:ZTS)Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Zoetis Right Now?Before you consider Zoetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.

While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

-

Saccaro’s Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With Mr. Saccaro’s appointment, Wetteny Joseph will transition to an advisory role effective August 17, 2026. Mr. Joseph has agreed to remain with the company as a Special Advisor to the CEO on financial matters until early 2027 to facilitate a smooth transition.

Mr. Saccaro joins Zoetis with extensive executive leadership experience at large-scale life sciences companies. He most recently served as Vice President and CFO at GE HealthCare, where he led key initiatives for the newly established public company, including designing processes and approaches across finance, accounting, new product planning, R&D prioritization, and capital allocation, and overseeing the Information Technology function. Previously, Mr. Saccaro spent over two decades at Baxter International Inc., where he held positions of increasing responsibility, culminating in his role as Executive Vice President and CFO for eight years. In that role, he oversaw all aspects of the company’s finance and information technology functions and led a number of high-impact enterprise initiatives, including a margin and cash flow improvement plan following the company's successful spin-off of Baxalta. Mr. Saccaro led business development for Baxter’s $5 billion Medication Delivery unit and played a key role in major M&A.

“We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth,” said Kristin Peck, Chief Executive Officer of Zoetis. “Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives. Jay’s track record of designing financial frameworks that balance R&D investment with operational rigor and efficiency will be a significant asset as we sharpen our competitive edge and invest in our future growth platforms. In this expanded role, Jay will also continue to strengthen our global manufacturing and supply operations, enhancing supply chain and distribution performance, and driving greater operational excellence and agility. I look forward to partnering with Jay to build on our industry leadership and deliver sustainable growth and long-term value for shareholders.”

“I am thrilled to join the world’s leading animal health company,” said Mr. Saccaro. “From the company’s deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care. There is tremendous runway to build on that legacy, and alongside Kristin, the leadership team and Zoetis’ talented colleagues, I’m eager to help unlock the opportunities ahead and drive sustainable value creation.”

Ms. Peck added, “On behalf of the Board of Directors and the entire Zoetis team, I thank Wetteny for his strong leadership, partnership, and many important contributions since joining the company five years ago. During his time with Zoetis, Wetteny has helped guide the company through a period of significant investment, change, and growth. We are grateful for his support through this transition and wish him all the best in his next chapter.”

“I am honored to have served as CFO of Zoetis and proud of our team’s accomplishments during my time with the company,” said Mr. Joseph. “I remain confident in Zoetis’ strategy, people and long-term opportunities. Zoetis remains strongly positioned to continue innovating and leading the animal health industry, and I look forward to watching its success for years to come.”

About Jay Saccaro

James (Jay) Saccaro is an accomplished executive with extensive leadership experience across global healthcare and life sciences organizations. He joins Zoetis from GE HealthCare, where he served as Vice President and Chief Financial Officer since 2023, leading the company’s finance, information technology, strategy and business development functions. Prior to GE HealthCare, Mr. Saccaro served as Executive Vice President and CFO at Baxter International Inc. from 2015 to 2023, where he played a key role in leading the company’s post-spin transformation, margin improvement initiatives and capital structure optimization. Prior to rejoining Baxter, Mr. Saccaro was Senior Vice President and CFO at Hill-Rom Corporation. He had previously served as the Corporate Vice President and Treasurer of Baxter from 2011 to 2013. Mr. Saccaro originally joined Baxter in 2002 as manager of strategy for the BioScience business, and over the years assumed positions of increasing responsibility, including vice president of financial planning and vice president of finance for the company’s operations in Europe, Middle East and Africa. He began his career in strategic planning at The Walt Disney Company.

Mr. Saccaro received a bachelor’s degree in economics and master’s degree in engineering-economic systems from Stanford University.

About Zoetis

Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

ZTS-COR
ZTS-IR
ZTS-FIN

More News From Zoetis Inc.

Back to Newsroom

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026.

The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis.

Adjusted net income2 for the second quarter of 2026 was $781 million, or $1.87 per diluted share, decreasing 1% and increasing 5%, respectively, on a reported basis, decreasing 2% and increasing 4%, respectively, on an organic operational basis. Adjusted net income for the second quarter of 2026 excludes the net impact of $90 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

"Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said Kristin Peck, Chief Executive Officer of Zoetis. "At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance. We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health. We also continue to benefit from the breadth of our diversified portfolio, including strength in Livestock and Diagnostics. As we advance our robust pipeline, including more than 12 potential blockbusters over the coming years, we are acting with urgency and remain confident in the long-term fundamentals of animal health and in Zoetis' ability to compete, lead, and create shareholder value."

SEGMENT HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2026:

Revenue in the U.S. segment totaled $1.3 billion, decreasing 7% on both a reported and an organic operational basis relative to the second quarter of 2025. Companion animal product sales decreased 11% due to continued softer end-market demand. The company's key dermatology franchise and Simparica Trio® faced persistent macro-driven price sensitivity and heightened competitive pressure. Also contributing to the decline was the impact of generic competition on the Cerenia® and Convenia® brands, as well as lower sales of Librela®. Sales of livestock products increased 23% on both a reported and organic operational basis in the quarter, supported by strength across cattle and poultry. Cattle performance was underpinned by favorable producer economics in beef cattle and supply timing. Poultry performance benefited from increased vaccine sales tied to disease outbreak activity. Revenue in the International segment was $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with the second quarter of 2025. Companion animal product sales grew 8% on a reported basis and 5% on an organic operational basis, led by the company's parasiticides portfolio, including Simparica Trio, along with contributions from Revolution® and Stronghold®. Also contributing to growth was companion animal diagnostics, as well as osteoarthritis (OA) pain with the launch of Lenivia® and Portela™, the company's long-acting monoclonal antibody pain products that provide dogs and cats with up to three months of pain relief. These gains were partially offset by lower sales of key dermatology products as well as challenging market conditions impacting the broader portfolio. Sales of livestock products grew 8% on a reported basis and 6% on an organic operational basis, driven by growth in cattle and poultry. INVESTMENTS IN GROWTH
Zoetis continued to advance innovation across its diversified portfolio, including a pipeline with more than 12 potential blockbuster3 candidates in areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity. During the quarter, the company advanced major-market approvals, expanded access to industry-leading treatments in new geographies, enhanced diagnostics capabilities, and delivered solutions to support customers facing emerging and transboundary infectious disease threats. Together, these efforts reflect Zoetis' focus on translating science, global scale and customer insights into solutions that improve the health of companion animals and livestock around the world.

Delivering on Commitment to Innovation
Zoetis is executing on its commitment to deliver a significant approval in a major market every year for the next several years. In July, the company received marketing authorization from the European Commission for Poulvac® Procerta® HVT-ND. This approval reinforces Zoetis’ focus on ensuring a stable and reliable protein supply, helping protect poultry production against Newcastle and Marek’s disease.

Lenivia and Portela, long-acting monoclonal antibody therapies providing dogs and cats with up to three months of OA pain relief from a single injection, launched in Canada and the EU and were approved in Great Britain. Lenivia was also approved in Switzerland.

Supporting Prevention and Treatment of New World Screwworm
With New World screwworm now confirmed in the United States, Zoetis has been well prepared to support customers’ prevention and treatment strategies. Dectomax®-CA1, the first parasite control product to receive FDA conditional approval for the prevention and treatment of New World screwworm myiasis in beef cattle, together with Dectomax®, received emergency use authorization in the U.S. for prevention of infestations in swine, sheep, deer, horses, lactating and dry dairy cows, and dairy replacement heifers. This response underscores Zoetis’ long-standing support for a One Health approach and its ability to deliver targeted solutions when disease threats affect animals, customers, and the broader food supply.

Additional approvals from the quarter include:

Vanguard® crLyme received a label update in the U.S. for effectiveness against subclinical arthritis caused by Borrelia burgdorferi, representing a significant pipeline acceleration. Bonqat®, an oral medication to help alleviate acute anxiety and fear associated with transportation and veterinary visits in cats, was approved in China. Synovex® One Grower gained an expanded label approval in the U.S. to increase the rate of weight gain in growing beef steers and heifers in dry lots or on pasture with insufficient forage. Suvaxyn® PRRS Needle-Free Microdose, a vaccine that helps prevent porcine reproductive and respiratory syndrome, was approved in the EU. This approval includes a needle free intramuscular administration claim and a new multidose presentation. Fostera® Gold PVC MH Flex, a vaccine to help prevent infection from Mycoplasma hyopneumoniae and Porcine circovirus, was approved in Japan. Accelerating Diagnostics Capabilities
In July, Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform. This milestone advances Zoetis’ strategic pursuit of opportunities that unlock new sources of growth by expanding its Global Diagnostics offering with around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. The acquisition will extend Zoetis’ capabilities beyond in-vitro testing into veterinary imaging interpretation and advance its vision of a more complete end-to-end Virtual Reference Lab.

Zoetis also expanded the capabilities of Vetscan Opticell™, making it the first and only point of care hematology analyzer to offer cellular hemoglobin mean – previously available only in reference laboratories. This expansion adds greater diagnostic depth in clinics and delivers value to veterinary teams through time, cost, and space savings.

Together, these investments strengthen Zoetis’ diagnostics capabilities and reinforce the company’s differentiated position in animal health with scale across both diagnostics and therapeutics.

Advancing Sustainability in Animal Health for a Better Future
In June, Zoetis published its 2025 Sustainability Report, marking the completion of its initial Driven to Care aspirations set in 2021 and introducing the strategy’s next phase, with an even sharper focus across Communities, Animals and the Planet. The report also highlighted that the Zoetis Foundation fulfilled its commitment to distribute $35 million in grants from 2021 to 2025, helping strengthen the animal health ecosystem by advancing opportunities for veterinary professionals and livestock farmers.

FINANCIAL GUIDANCE
Zoetis is providing updated guidance based on the current operating environment.

Revenue of $9.120 billion to $9.320 billion (organic operational growth of (3)% to (1)%) Reported net income of $2.330 billion to $2.380 billion Adjusted net income of $2.570 billion to $2.620 billion (organic operational growth of (9)% to (5)%) Reported diluted EPS of $5.55 to $5.65 Adjusted diluted EPS of $6.15 to $6.25 This guidance reflects foreign exchange rates as of July 21, 2026. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call.

WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call today at 8:30 a.m. ET to review second quarter 2026 results, discuss financial guidance and respond to questions from financial analysts. The live webcast and corresponding slides can be accessed by visiting https://investor.zoetis.com/events-presentations. A replay of the webcast will be available following the event.

About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
3 A blockbuster has annual sales of at least $100 million.

DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; possible impacts of the Fiscal Year Alignment; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

ZTS-COR
ZTS-IR
ZTS-FIN

ZOETIS INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

(millions of dollars, except per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2026

2025

% Change

2026

2025

% Change

Revenue

$

2,468

$

2,474

—

$

4,730

$

4,672

1

Costs and expenses:

Cost of sales

673

664

1

1,314

1,282

2

Selling, general and administrative expenses

592

614

(4

)

1,180

1,188

(1

)

Research and development expenses

173

166

4

353

328

8

Amortization of intangible assets

31

33

(6

)

62

65

(5

)

Restructuring charges and certain acquisition and divestiture-related costs

77

30

*

99

30

*

Interest expense, net of capitalized interest

61

53

15

123

107

15

Other (income)/deductions–net

(5

)

2

*

(25

)

(13

)

92

Income before provision for taxes on income

866

912

(5

)

1,624

1,685

(4

)

Provision for taxes on income

175

186

(6

)

332

357

(7

)

Net income before allocation to noncontrolling interests

691

726

(5

)

1,292

1,328

(3

)

Less: Net income/(loss) attributable to noncontrolling interests

—

—

*

—

—

*

Net income attributable to Zoetis Inc.

$

691

$

726

(5

)

$

1,292

$

1,328

(3

)

Earnings per share attributable to Zoetis—basic

$

1.65

$

1.63

1

$

3.08

$

2.98

3

Earnings per share attributable to Zoetis—diluted

$

1.65

$

1.63

1

$

3.08

$

2.97

4

Weighted-average shares used to calculate earnings per share

Basic

417.6

445.1

419.9

446.3

Diluted

417.7

445.5

420.1

446.7

* Calculation not meaningful.

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

Three Months Ended June 30, 2026

GAAP Reported

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(a)

Cost of sales

$

673

$

(1

)

$

—

$

(3

)

$

669

Gross profit

1,795

1

—

3

1,799

Selling, general and administrative expenses

592

(3

)

—

(3

)

586

Amortization of intangible assets

31

(26

)

—

—

5

Restructuring charges and certain acquisition and divestiture-related costs

77

—

(2

)

(75

)

—

Income before provision for taxes on income

866

30

2

81

979

Provision for taxes on income

175

6

—

17

198

Net income attributable to Zoetis

691

24

2

64

781

Earnings per common share attributable to Zoetis–diluted

1.65

0.06

—

0.16

1.87

Three Months Ended June 30, 2025

GAAP Reported

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(a)

Cost of sales

$

664

$

(1

)

$

—

$

(2

)

$

661

Gross profit

1,810

1

—

2

1,813

Selling, general and administrative expenses

614

(2

)

—

(9

)

603

Research and development expenses

166

(1

)

—

—

165

Amortization of intangible assets

33

(29

)

—

—

4

Restructuring charges and certain acquisition and divestiture-related costs

30

—

(1

)

(29

)

—

Other (income)/deductions–net

2

—

—

(8

)

(6

)

Income before provision for taxes on income

912

33

1

48

994

Provision for taxes on income

186

8

—

9

203

Net income attributable to Zoetis

726

25

1

39

791

Earnings per common share attributable to Zoetis–diluted

1.63

0.06

—

0.09

1.78

(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

  ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

Six Months Ended June 30, 2026

GAAP Reported

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(a)

Cost of sales

$

1,314

$

(2

)

$

—

$

(5

)

$

1,307

Gross profit

3,416

2

—

5

3,423

Selling, general and administrative expenses

1,180

(2

)

—

(7

)

1,171

Research and development expenses

353

(1

)

—

—

352

Amortization of intangible assets

62

(53

)

—

—

9

Restructuring charges and certain acquisition and divestiture-related costs

99

—

(4

)

(95

)

—

Other (income)/deductions–net

(25

)

—

—

(1

)

(26

)

Income before provision for taxes on income

1,624

58

4

108

1,794

Provision for taxes on income

332

13

1

21

367

Net income attributable to Zoetis

1,292

45

3

87

1,427

Earnings per common share attributable to Zoetis–diluted

3.08

0.11

—

0.21

3.40

Six Months Ended June 30, 2025

GAAP Reported

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(a)

Cost of sales

$

1,282

$

(2

)

$

—

$

(2

)

$

1,278

Gross profit

3,390

2

—

2

3,394

Selling, general and administrative expenses

1,188

(5

)

—

(15

)

1,168

Research and development expenses

328

(1

)

—

—

327

Amortization of intangible assets

65

(57

)

—

—

8

Restructuring charges and certain acquisition and divestiture-related costs

30

—

(1

)

(29

)

—

Other (income)/deductions–net

(13

)

—

—

(8

)

(21

)

Income before provision for taxes on income

1,685

65

1

54

1,805

Provision for taxes on income

357

15

—

9

381

Net income attributable to Zoetis

1,328

50

1

45

1,424

Earnings per common share attributable to Zoetis–diluted

2.97

0.12

—

0.10

3.19

(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars)

(1) Acquisition and divestiture-related costs include the following:

Three Months Ended

Six Months Ended

June 30,

June 30,

2026

2025

2026

2025

Acquisition-related costs(a)

$

2

$

1

$

4

$

1

Total acquisition and divestiture-related costs—pre-tax

2

1

4

1

Income taxes(b)

—

—

1

—

Total acquisition and divestiture-related costs—net of tax

$

2

$

1

$

3

$

1

  (a) Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.

(b) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

(2) Certain significant items include the following:

Three Months Ended

Six Months Ended

June 30,

June 30,

2026

2025

2026

2025

Other restructuring charges and cost-reduction/productivity initiatives(a)

$

75

$

7

$

95

$

7

Business process transformation program(b)

6

11

11

18

Certain asset impairment charges(c)

—

27

—

27

Net loss on sale of business(d)

—

3

—

3

Other

—

—

2

(1

)

Total certain significant items—pre-tax

81

48

108

54

Income taxes(e)

17

9

21

9

Total certain significant items—net of tax

$

64

$

39

$

87

$

45

  (a) For the three and six months ended June 30, 2026, primarily driven by employee termination costs under a comprehensive cost and productivity program, with the six-month period also reflecting employee termination costs from additional organizational structure refinements.

For the three and six months ended June 30, 2025, primarily consisted of employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs.

(b) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs, included in Selling, general and administrative expenses and Cost of sales. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.

(c) Represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs, as well as charges related to our aquaculture product portfolio included in Other (income)/deductions–net.

(d) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024, included in Other (income)/deductions–net.

(e) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

  ZOETIS INC.

ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)

(UNAUDITED)

(millions of dollars)

  Three Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Adjusted cost of sales

$

669

$

661

1

%

3

%

(2

)%

as a percent of revenue

27.1

%

26.7

%

NA

NA

NA

Adjusted SG&A expenses

586

603

(3

)%

1

%

(4

)%

Adjusted R&D expenses

173

165

5

%

1

%

4

%

Adjusted net income

781

791

(1

)%

1

%

(2

)%

—

%

(2

)%

Six Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Adjusted cost of sales

$

1,307

$

1,278

2

%

6

%

(4

)%

as a percent of revenue

27.6

%

27.4

%

NA

NA

NA

Adjusted SG&A expenses

1,171

1,168

—

%

2

%

(2

)%

Adjusted R&D expenses

352

327

8

%

2

%

6

%

Adjusted net income

1,427

1,424

—

%

1

%

(1

)%

—

%

(1

)%

(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

2026 GUIDANCE

  Selected Line Items

(millions of dollars, except per share amounts)

Full Year 2026

as of August 6, 2026

Full Year 2026

as of May 7, 2026

(Prior Guidance)

Revenue

$9,120 to $9,320

$9,680 to $9,960

Organic operational results(a)

(3)% to (1)%

2% to 5%

Adjusted cost of sales as a percentage of revenue(b)

Approximately 29.0%

Approximately 28.5%

Adjusted SG&A expenses(b)

$2,330 to $2,380

$2,350 to $2,400

Adjusted R&D expenses(b)

$720 to $730

$735 to $745

Adjusted interest expense and other (income)/deductions-net(b)

Approximately $215

Approximately $215

Effective tax rate on adjusted income(b)

Approximately 20.5%

Approximately 20.5%

Adjusted diluted EPS(b)

$6.15 to $6.25

$6.85 to $7.00

Adjusted net income(b)

$2,570 to $2,620

$2,870 to $2,950

Organic operational results(a)(c)

(9)% to (5)%

2% to 6%

Certain significant items and acquisition and divestiture-related costs(d)

Approximately $150

Approximately $100

Reported diluted EPS

$5.55 to $5.65

$6.35 to $6.50

The guidance reflects foreign exchange rates as of July 21, 2026.

Reconciliations of 2026 reported guidance to 2026 adjusted guidance follows:

  (millions of dollars, except per share amounts) Reported

Certain significant items and acquisition and divestiture-related costs(d)

Purchase accounting

Adjusted(b)

Cost of sales as a percentage of revenue

~ 29.2%

~ (0.2%)

~ 29.0%

SG&A expenses

$2,350 to $2,400

~ $(12)

~ $(8)

$2,330 to $2,380

R&D expenses

$722 to $732

~ $(2)

$720 to $730

Interest expense and other (income)/deductions-net

~ $215

~ $215

Effective tax rate

~ 20.6%

~ (0.1%)

~ 20.5%

Diluted EPS

$5.55 to $5.65

~ $0.38

~ $0.22

$6.15 to $6.25

Net income attributable to Zoetis

$2,330 to $2,380

~ $150

~ $90

$2,570 to $2,620

  (a) Organic operational results (a non-GAAP financial measure) excludes the impact of foreign exchange and certain acquisitions and divestitures.

(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.

(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Revenue:

Companion Animal

$

1,708

$

1,790

(5

)%

1

%

(6

)%

—

%

(6

)%

Livestock

731

651

12

%

2

%

10

%

(1

)%

11

%

Contract Manufacturing & Human Health

29

33

(12

)%

1

%

(13

)%

—

%

(13

)%

Total Revenue

$

2,468

$

2,474

—

%

2

%

(2

)%

(1

)%

(1

)%

U.S.:

Companion Animal

$

1,044

$

1,176

(11

)%

—

%

(11

)%

—

%

(11

)%

Livestock

222

180

23

%

—

%

23

%

—

%

23

%

Total U.S. Revenue

$

1,266

$

1,356

(7

)%

—

%

(7

)%

—

%

(7

)%

International:

Companion Animal

$

664

$

614

8

%

3

%

5

%

—

%

5

%

Livestock

509

471

8

%

4

%

4

%

(2

)%

6

%

Total International Revenue

$

1,173

$

1,085

8

%

3

%

5

%

(1

)%

6

%

Companion Animal:

Dogs and Cats

$

1,634

$

1,719

(5

)%

1

%

(6

)%

Horses

74

71

4

%

1

%

3

%

Total Companion Animal Revenue

$

1,708

$

1,790

(5

)%

1

%

(6

)%

Livestock:

Cattle

$

390

$

323

21

%

3

%

18

%

Swine

117

118

(1

)%

2

%

(3

)%

Poultry

115

104

11

%

1

%

10

%

Fish

83

81

2

%

4

%

(2

)%

Sheep and other

26

25

4

%

8

%

(4

)%

Total Livestock Revenue

$

731

$

651

12

%

2

%

10

%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

Six Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Revenue:

Companion Animal

$

3,227

$

3,331

(3

)%

2

%

(5

)%

—

%

(5

)%

Livestock

1,451

1,278

14

%

4

%

10

%

(1

)%

11

%

Contract Manufacturing & Human Health

52

63

(17

)%

1

%

(18

)%

—

%

(18

)%

Total Revenue

$

4,730

$

4,672

1

%

2

%

(1

)%

—

%

(1

)%

U.S.:

Companion Animal

$

1,909

$

2,149

(11

)%

—

%

(11

)%

—

%

(11

)%

Livestock

447

390

15

%

—

%

15

%

—

%

15

%

Total U.S. Revenue

$

2,356

$

2,539

(7

)%

—

%

(7

)%

—

%

(7

)%

International:

Companion Animal

$

1,318

$

1,182

12

%

6

%

6

%

—

%

6

%

Livestock

1,004

888

13

%

5

%

8

%

(2

)%

10

%

Total International Revenue

$

2,322

$

2,070

12

%

5

%

7

%

(1

)%

8

%

Companion Animal:

Dogs and Cats

$

3,077

$

3,196

(4

)%

2

%

(6

)%

Horses

150

135

11

%

3

%

8

%

Total Companion Animal Revenue

$

3,227

$

3,331

(3

)%

2

%

(5

)%

Livestock:

Cattle

$

782

$

664

18

%

4

%

14

%

Swine

240

223

8

%

4

%

4

%

Poultry

233

210

11

%

2

%

9

%

Fish

149

136

10

%

7

%

3

%

Sheep and other

47

45

4

%

7

%

(3

)%

Total Livestock Revenue

$

1,451

$

1,278

14

%

4

%

10

%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS

(UNAUDITED)

(millions of dollars)

  Three Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Divestitures

Organic Operational(a)

Total International

$

1,173

$

1,085

8

%

3

%

(1

)%

6

%

Australia

94

83

13

%

11

%

—

%

2

%

Brazil

103

93

11

%

11

%

—

%

—

%

Canada

72

71

1

%

—

%

(5

)%

6

%

Chile

34

34

—

%

—

%

—

%

—

%

China

62

67

(7

)%

7

%

—

%

(14

)%

France

40

42

(5

)%

3

%

—

%

(8

)%

Germany

69

57

21

%

2

%

—

%

19

%

Italy

40

37

8

%

1

%

—

%

7

%

Japan

41

43

(5

)%

(11

)%

—

%

6

%

Mexico

47

39

21

%

15

%

—

%

6

%

Spain

43

40

8

%

2

%

(1

)%

7

%

United Kingdom

72

81

(11

)%

(1

)%

(1

)%

(9

)%

Other developed markets

187

175

7

%

3

%

—

%

4

%

Other emerging markets

269

223

21

%

1

%

(1

)%

21

%

Six Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Divestitures

Organic Operational(a)

Total International

$

2,322

$

2,070

12

%

5

%

(1

)%

8

%

Australia

183

162

13

%

11

%

—

%

2

%

Brazil

193

174

11

%

11

%

—

%

—

%

Canada

145

141

3

%

3

%

(6

)%

6

%

Chile

72

69

4

%

2

%

—

%

2

%

China

125

122

2

%

5

%

—

%

(3

)%

France

77

81

(5

)%

6

%

—

%

(11

)%

Germany

128

112

14

%

6

%

—

%

8

%

Italy

79

67

18

%

8

%

(1

)%

11

%

Japan

76

75

1

%

(8

)%

—

%

9

%

Mexico

95

74

28

%

16

%

—

%

12

%

Spain

83

69

20

%

7

%

(1

)%

14

%

United Kingdom

150

155

(3

)%

3

%

(1

)%

(5

)%

Other developed markets

356

308

16

%

7

%

—

%

9

%

Other emerging markets

560

461

21

%

1

%

(1

)%

21

%

(a) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Operational(b)

U.S.:

Revenue

$

1,266

$

1,356

(7

)%

—

%

(7

)%

Cost of Sales

214

208

3

%

—

%

3

%

Gross Profit

1,052

1,148

(8

)%

—

%

(8

)%

Gross Margin

83.1

%

84.7

%

Operating Expenses

215

218

(1

)%

—

%

(1

)%

Other (income)/deductions-net

—

—

*

*

*

U.S. Earnings

$

837

$

930

(10

)%

—

%

(10

)%

International:

Revenue

$

1,173

$

1,085

8

%

3

%

5

%

Cost of Sales

340

321

6

%

4

%

2

%

Gross Profit

833

764

9

%

3

%

6

%

Gross Margin

71.0

%

70.4

%

Operating Expenses

172

171

1

%

3

%

(2

)%

Other (income)/deductions-net

—

1

*

*

*

International Earnings

$

661

$

592

12

%

4

%

8

%

Total Reportable Segments

$

1,498

$

1,522

(2

)%

1

%

(3

)%

Other business activities(c)

(135

)

(129

)

5

%

Reconciling Items:

Corporate(d)

(315

)

(324

)

(3

)%

Purchase accounting adjustments(e)

(30

)

(33

)

(9

)%

Acquisition and divestiture-related costs(f)

(2

)

(1

)

*

Certain significant items(g)

(81

)

(48

)

69

%

Other unallocated(h)

(69

)

(75

)

(8

)%

Total Earnings(i)

$

866

$

912

(5

)%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

  ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

Six Months Ended

June 30,

% Change

2026

2025

Reported Change

Foreign Exchange

Operational(b)

U.S.:

Revenue

$

2,356

$

2,539

(7

)%

—

%

(7

)%

Cost of Sales

408

407

—

%

—

%

—

%

Gross Profit

1,948

2,132

(9

)%

—

%

(9

)%

Gross Margin

82.7

%

84.0

%

Operating Expenses

414

423

(2

)%

—

%

(2

)%

Other (income)/deductions-net

—

—

*

*

*

U.S. Earnings

$

1,534

$

1,709

(10

)%

—

%

(10

)%

International:

Revenue

$

2,322

$

2,070

12

%

5

%

7

%

Cost of Sales

674

616

9

%

6

%

3

%

Gross Profit

1,648

1,454

13

%

4

%

9

%

Gross Margin

71.0

%

70.2

%

Operating Expenses

347

334

4

%

5

%

(1

)%

Other (income)/deductions-net

1

1

*

*

*

International Earnings

$

1,300

$

1,119

16

%

5

%

11

%

Total Reportable Segments

$

2,834

$

2,828

—

%

2

%

(2

)%

Other business activities(c)

(276

)

(262

)

5

%

Reconciling Items:

Corporate(d)

(630

)

(602

)

5

%

Purchase accounting adjustments(e)

(58

)

(65

)

(11

)%

Acquisition and divestiture-related costs(f)

(4

)

(1

)

*

Certain significant items(g)

(108

)

(54

)

*

Other unallocated(h)

(134

)

(159

)

(16

)%

Total Earnings(i)

$

1,624

$

1,685

(4

)%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

  More News From Zoetis Inc.

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zoetis securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.   

[Click here for information about joining the class action]  

On May 7, 2026, Zoetis reported financial results for the first quarter of 2026.  Among other items, Zoetis reported net income of $601 million, flat year over year, and cut its full year 2026 profit guidance to between $6.85 and $7 a share, down from prior guidance of $7.00 to $7.10 a share.  In the earnings release, CEO Kristin Peck said that “the first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand[.]” 

On this news, Zoetis’s stock price fell $23.91 per share, or 21.5%, to close at $87.31 per share on May 7, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT: 
Danielle Peyton 
Pomerantz LLP 
[email protected] 
646-581-9980 ext. 7980 

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until July 27, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zoetis securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

[Click here for information about joining the class action]

On May 7, 2026, Zoetis reported financial results for the first quarter of 2026. Among other items, Zoetis reported net income of $601 million, flat year over year, and cut its full year 2026 profit guidance to between $6.85 and $7 a share, down from prior guidance of $7.00 to $7.10 a share. In the earnings release, CEO Kristin Peck said that “the first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand[.]”

On this news, Zoetis’s stock price fell $23.91 per share, or 21.5%, to close at $87.31 per share on May 7, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980